Bill Gates Launches ‘Self-Assembling Contraceptive Implants’ to Reduce Population

Billionaire Bill Gates is funding a chilling new “microcrystal implant” contraceptive that “self-assembles” inside the body to shut down fertility and reduce global population numbers.

The new injectable platform was funded by the Microsoft co-founder’s Gates Foundation and developed by researchers from MIT, Harvard Medical School, and the Broad Institute.

This from slaynews.com.

A study, published in Nature Chemical Engineering, reveals these injections harden into a solid mass under the skin. The implants then release hormones to block pregnancy, which multiply inside the body with no way to remove them.

In animal testing, the implants lasted months. In humans, however, they could persist for years, raising the risk of irreversible sterilization, especially in poor nations with no access to surgery to remove the devices. Meanwhile, Gates is bankrolling studies forecasting population collapse, while promoting technologies that would only speed it up, from “universal vaccines” to permanent implants.

The Gates Foundation is promoting the new implants as a “nonsurgical option for women.” The devices are aimed at lowering population numbers by reducing birth rates, particularly among those considered to be “useless” by the globalist elite.

The researchers argue the new technology has the potential to be used for future adaptation to neuropsychiatric and infectious diseases. However, the self-assembling drug delivery mechanism raises serious safety, ethical, and biosecurity concerns.

The new technology was detailed in Nature Chemical Engineering and reported by Healio. The injections deliver the long-acting contraceptive levonorgestrel through self-aggregating long-acting injectable microcrystals, or “SLIM.” The microcrystals form an implant inside the recipient’s body after injection.

Giovanni Traverso, MD, BChir, PhD, associate professor at MIT and a physician at Harvard Medical School, explained:

Once injected, the drug microcrystals self-aggregate in the subcutaneous space to form a monolithic implant.

In a press release, the researchers described the mechanism:

[As] like tiny puzzle pieces that, once injected inside the body, undergo solvent exchange to assemble into a single solid implant that slowly releases the drug as the surface erodes.

This solvent-exchange crystallization process allows for “prolonged drug release” without requiring surgery. It also enables administration with an ultra-thin 30-gauge needle

The technology bypasses traditional medical oversight and dramatically increases the possibility of self-administration. And the researchers claim that self-administration would improve accessibility and “medication use.” But this radical convenience comes at a cost.

Traverso explained the driving motivation behind the project:

The challenge is that people do not like injections.

Further:

Is there a way to engineer something to help overcome those types of challenges? That is our focus.

Their solution was to use a solvent that solubilizes the drug during injection. The solvent will then “go away” in the body, leaving behind the crystallized drug structure.

Traverso told Healio:

What we were able to figure out is by using a solvent or fluid that can help solubilize the drug, we could load that solution in a way that, when injected, that solvent would go away and leave behind that solid depot of drug.

Further:

Because it is fluid and we are loading it, it is much easier to inject. That was critical.

And:

We also wanted that object to be solid enough that we could retrieve it if we needed to.

He explained:

The goal was a drug platform that could be injected easily yet form a physically solid implant that may be removable if required.

However, the method of removing the implant post-aggregation is unclear.

According to Healio:

[T]he solvent-exchange-mediated aggregation mechanism allows injections through needles as small as 30 G with no polymer and 25 G with a small amount of polymer while extending the drug release time frame.

Histological studies allegedly confirmed the drug platform was “well tolerated.”

The Gates-funded researchers are now hoping the technology’s applications could extend beyond contraception.

The researchers wrote:

Specifically, in applications such as contraception, SLIM’s capability for prolonged drug release could significantly reduce the frequency of administration compared with current self-administerable options such as Depo-Provera and Sayana Press.

But they do not intend to stop at contraceptives.

Traverso said:

[T]he researchers are still actively working on the platform and applying it to several other infectious and neuropsychiatric conditions.

Further:

From a manufacturing standpoint, this [design] is simple and low cost.

And:

This work was funded by the Gates Foundation, an organization that considers those aspects from an early stage.

He concluded:

We hope to be in humans [with this technology] within the next 3 to 5 years, assuming further funding.

The Gates Foundation is now backing a self-assembling drug delivery platform designed for low-cost mass production, self-injection, and potential fertility suppression. The developers plan to expand the use of the technology to psychiatric drugs and vaccines.

The Gates Foundation, MIT engineering, and the Broad Institute want their self-assembling technology to be injected into humans by 2028. Notably, Bill Gates supports depopulation and has previously promoted the use of vaccines and contraceptives to achieve this objective.

During a 2010 TED Talk, Gates stated:

[I]f we do a really great job on new vaccines, health care, reproductive health services, we could lower [the world population] by, perhaps, 10 or 15 percent.